Table 3 Patient Stratification by Ethnicity
| Â | # of Patients (%) | ||
|---|---|---|---|
Characteristic | Hispanic | NH | P Value |
Age (yrs) (n = 86) | Â | Â | 1 |
   <60 | 49 (92.5%) | 30 (90.9%) |  |
   >/=60 | 4 (7.5%) | 3 (9.1%) |  |
Gender (n = 87) | Â | Â | 0.19 |
   Female | 23 (43.4%) | 20 (58.8%) |  |
   Male | 30 (56.6%) | 14 (41.2%) |  |
Hemoglobin (g/dL) (n = 83) | Â | Â | 1 |
   <12 | 34 (68%) | 23 (69.7%) |  |
   >/=12 | 16 (32%) | 10 (30.3%) |  |
Leukocyte count (× 109/L) (n = 85) |  |  | 0.13 |
   <50 | 10 (10.6%) | 12 (35.3%) |  |
   >/=50 | 41 (80.4%) | 22 (64.7%) |  |
Platelets (× 109/L) (n = 82) |  |  | 0.64 |
   <450 | 29 (58%) | 21 (65.6%) |  |
   >/=450 | 21 (42%) | 11 (34.4%) |  |
Hasford Score (n = 64) | Â | Â | 0.046 |
   </=780 low-risk | 23 (56.1%) | 12 (52.2%) |  |
   >780 and </=1480 intermediate | 16 (39.0%) | 5 (21.7%) |  |
   >1480 high-risk | 2 (4.9%) | 6 (26.1%) |  |
Sokal Score (n = 65) | Â | Â | 0.11 |
   <0.8 good prognosis | 19 (45.2%) | 6 (26.1%) |  |
   0.8–1.2 moderate prognosis | 16 (38.1%) | 8 (34.8%) |  |
   >1.2 poor prognosis | 7 (16.7%) | 9 (39.1%) |  |
CHR at 3 months, all treatments (n = 47) | Â | Â | 0.016 |
   Yes | 20 (76.9%) | 8 (38.1%) |  |
   No | 6 (23.1%) | 13 (61.9%) |  |
CHR at 3 months, imatinib only (n = 36) | Â | Â | 0.23 |
   Yes | 19 (82.6%) | 8 (61.5%) |  |
   No | 4 (17.4%) | 5 (38.5%) |  |